SARS-CoV-2 Vaccination and Myocarditis in a Nordic Cohort Study of 23 Million Residents

Key Points Question Is SARS-CoV-2 messenger RNA (mRNA) vaccination associated with risk of myocarditis? Findings In a cohort study of 23.1 million residents across 4 Nordic countries, risk of myocarditis after the first and second doses of SARS-CoV-2 mRNA vaccines was highest in young males aged 16 to 24 years after the second dose. For young males receiving 2 doses of the same vaccine, data were compatible with between 4 and 7 excess events in 28 days per 100 000 vaccinees after second-dose BNT162b2, and between 9 and 28 per 100 000 vaccinees after second-dose mRNA-1273. Meaning The risk of myocarditis in this large cohort study was highest in young males after the second SARS-CoV-2 vaccine dose, and this risk should be balanced against the benefits of protecting against severe COVID-19 disease.

[1]  S. Gharbia,et al.  Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant , 2022, The New England journal of medicine.

[2]  G. Ioannou,et al.  Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system , 2022, eClinicalMedicine.

[3]  K. Spiess,et al.  Transmission of SARS-CoV-2 Omicron VOC subvariants BA.1 and BA.2: Evidence from Danish Households , 2022, medRxiv.

[4]  Manfred S. Green,et al.  Myocarditis after BNT162b2 Vaccination in Israeli Adolescents , 2022, The New England journal of medicine.

[5]  Michael John Smith,et al.  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.

[6]  B. Long,et al.  Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation , 2022, The American Journal of Emergency Medicine.

[7]  Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines , 2022, Reactions Weekly.

[8]  H. Sørensen,et al.  SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study , 2021, BMJ.

[9]  K. Khunti,et al.  Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection , 2021, Nature Medicine.

[10]  R. Gedeborg,et al.  The profile of the COvid-19 VACcination register SAFEty study in Sweden (CoVacSafe-SE) , 2021, Upsala journal of medical sciences.

[11]  M. Hernán,et al.  Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans , 2021, New England Journal of Medicine.

[12]  R. Balicer,et al.  Adverse Effects after BNT162b2 Vaccine and SARS-CoV-2 Infection, According to Age and Sex , 2021, The New England journal of medicine.

[13]  Manfred S. Green,et al.  Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel , 2021, The New England journal of medicine.

[14]  R. Balicer,et al.  Myocarditis after Covid-19 Vaccination in a Large Health Care Organization , 2021, The New England journal of medicine.

[15]  J. Nelson,et al.  Surveillance for Adverse Events After COVID-19 mRNA Vaccination. , 2021, JAMA.

[16]  Ben Y. Reis,et al.  Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting , 2021, The New England journal of medicine.

[17]  M. Gissler,et al.  Nordic Health Registry-Based Research: A Review of Health Care Systems and Key Registries , 2021, Clinical epidemiology.

[18]  L. Cooper,et al.  Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military. , 2021, JAMA cardiology.

[19]  H. Sørensen,et al.  Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study , 2021, BMJ.

[20]  Fridtjof Lund-Johansen,et al.  Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.

[21]  Antonio Gasparrini,et al.  An extended mixed‐effects framework for meta‐analysis , 2019, Statistics in medicine.

[22]  P. Rautava,et al.  Occurrence and Features of Childhood Myocarditis: A Nationwide Study in Finland , 2017, Journal of the American Heart Association.

[23]  H. Bøtker,et al.  Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study , 2016, BMJ Open.

[24]  Gun Peggy Knudsen,et al.  Ethical aspects of registry-based research in the Nordic countries , 2015, Clinical epidemiology.

[25]  C. Pipper,et al.  [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.

[26]  W. G. Cochran.  The comparison of percentages in matched samples. , 1950, Biometrika.

[27]  G. Ioannou,et al.  Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System , 2022, SSRN Electronic Journal.